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Background:  Statin (St) therapy can be associated with a slightly increased risk of diabetes mellitus (DM) and insulin resistance in 
nonDM patients. In prior studies, ezetimibe (Eze)+St did not increase fasting serum glucose (FSG) more than St alone in St naïve, nonDM, 
hypercholesterolemic (HC) patients for up to 96 wks. This analysis assessed the effects of Eze on FSG changes when given to nonDM, HC 
patients on stable St therapy.
methods:  Data was pooled from 2 randomized, double blind, add on‡ (Eze added to stable St [n=1506] vs placebo [n=851] studies) for 8 
wks in nonDM patients at baseline (BL). Mean FSG changes from BL were estimated for each treatment group (LDA model¶) and between 
treatment differences calculated. Numbers of patients with FSG ≥126 mg/dl and effect of BL cofactors were also assessed.
results:  No significant FSG increases from BL were observed with St and Eze+St in add on studies; the between treatment group 
difference was also not significant (p>0.05; Figure). The lack of an Eze effect on FSG is consistent with prior findings in St naïve subjects 
comparing Eze+St vs St. FSG changes were not related to age, and BL BMI, HDL-C and TG, nor to changes from baseline in LDL-C, BMI, 
HDL-C, TG and ApoB. Proportions of patients with FSG ≥126 mg/dl during the trial were low, similar for St and Eze+St, and highest in 
those with BL FSG ≥100-≤126 mg/dL.
Conclusion:  In HC patients on stable St therapy, addition of Eze did not increase FSG levels more than St therapy, consistent with Eze+St 
therapy effects in St naïve patients.
 
